Clinical trial
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC)…
NCT00002032 · Pharmacia, Industry · Completed
Key facts
| NCT number | NCT00002032 |
|---|---|
| Title | Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial |
| Official title | Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial |
| Lead sponsor | Pharmacia, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Mycobacterium Avium-intracellulare Infection, HIV Infections |
| Intervention type | Drug |
| Interventions | Rifabutin |
| Enrollment | 750 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: